DOCSLIB.ORG

Preterm Neonates Show Marked Leukopenia and Lymphopenia That Are Associated with Increased Regulatory T-Cell Values and Diminished IL-7

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preterm Neonates Show Marked Leukopenia and Lymphopenia That Are Associated with Increased Regulatory T-Cell Values and Diminished IL-7 nature publishing group Articles Clinical Investigation Preterm neonates show marked leukopenia and lymphopenia that are associated with increased regulatory T-cell values and diminished IL-7 Rafael Correa-Rocha1, Alicia Pérez1, Raquel Lorente1, Sara Ferrando-Martínez1, Manuel Leal2, Dolores Gurbindo3, and M. Ángeles Muñoz-Fernández1 INTRODUCTiON: Current advances in neonatology have In fact, the most important factors that ­predispose to infection improved survival among preterm and low-birth-weight are prematurity and/or low birth weight. infants. However, the risk of neonatal death in preterm infants Little is known about innate immunity in premature neo- is much greater than in full-term neonates and is frequently nates and the capacity of their immune systems to fight against associated with infections. infections. Several authors have reported differences in pheno- METHODS: Little is known about the immune status of pre- type and function of lymphocytes between healthy ­newborns, term neonates; therefore, we analyzed the frequency and abso- children, and adults (5). The immune response of preterm lute counts of different immune populations in 211 cord blood infants is assumed to be immature, although quantitative samples taken from very-preterm to full-term neonates. data on differences in immune capacity between preterm and RESULTS: We found that absolute counts of all the immune ­full-term infants are scant. subsets analyzed (i.e., monocytes, granulocytes, B cells, natu- The objective of this study was to investigate whether the ral killer (NK) cells, CD4+, and CD8+ T cells) were markedly high incidence of infections in preterm infants could be due lower in preterm infants than in full-term infants. Surprisingly, to an immunodeficiency and, if so, to identify which immune we observed that regulatory T cells (Tregs) were the only cell cell populations are implicated in the absence of an adequate subset that did not decrease in preterm infants, and their fre- immune response. We performed a comprehensive analysis of quency was even higher than in full-term infants. the frequency and absolute counts of several cell populations DiSCUSSiON: Tregs are crucial to maternal–fetal tolerance, in preterm and full-term infants to establish immune status but their suppressive role could be also implicated in the leu- according to GA and weight. We also studied the presence of kopenia observed in preterm infants. We did not observe dif- regulatory T cells (Tregs) in preterm infants; this cell population ferences in thymic function, but we found that plasma levels of may play a key role in preventing immune deregulation result- interleukin (IL)-7 and the frequency of its receptor were signifi- ing in acute infections or chronic immune modulation. Tregs cantly decreased in preterm infants. Our results could help to play a crucial role in maternal–fetal tolerance, and their levels are identify leukopenia and to implement immune therapies that increased during pregnancy (6,7). However, little information is significantly diminish mortality in preterm neonates. available about the frequency of these cells in neonates, particu- larly in preterm infants, or about their potential role in immune ecent developments in neonatology and improvements in homeostasis during this period of life. Finally, establishing refer- Rtechnology to manage preterm neonates have significantly ence ranges for immune cell subpopulations in preterm infants increased the survival of very-preterm neonates (less than 28 wk could help the neonatologist to identify severe leukopenia and of gestation) and very-low-birth-weight infants (less than 1,500 g) thus prevent infections. In addition, it could constitute a tool for (1). However, the relative risk of neonatal death is much greater implementing immunostimulatory treatments that could sig- for preterm infants than for full-term infants, and prematurity nificantly decrease mortality in preterm infants. has become the leading cause of perinatal morbidity and mortal- ity (2,3). Along with decreasing gestational age (GA), low birth RESULTS weight is also associated with increased perinatal morbidity and We analyzed the percentage and absolute counts of different mortality (4). Among the causes responsible for this increased immune populations in fresh cord blood from 211 healthy mortality, neonatal sepsis and bronchopulmonary dysplasia are neonates. Infants were stratified into two groups according to the most frequent causes of death in premature newborns (3). GA, and differences between these groups were studied. The 1Laboratorio de Inmunobiología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain; 2Laboratorio de Inmunovirología, Instituto de Biomedicina de Sevilla, Hospital Virgen del Rocío, Sevilla, Spain; 3Sección de Inmunopediatría, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Correspondence: M. Ángeles Muñoz-Fernández ([email protected]) Received 08 July 2011; accepted 22 December 2011; advance online publication 7 March 2012. doi:10.1038/pr.2012.6 590 Pediatric RESEArCH Volume 71 | Number 5 | May 2012 Copyright © 2012 International Pediatric Research Foundation, Inc. Leukopenia in preterm infants and Tregs Articles preterm group comprised 117 infants with a GA <37 wk; the and increased mortality) in 97% of the studied samples (8). full-term group comprised 94 infants with a GA ≥ 37 wk. Therefore, no differences were established in the incidence of acidosis between preterm and full-term infants, and no Clinical Parameters correlation was established between prematurity and mater- The analysis of clinical parameters after delivery revealed nal age (P = 0.390) (Table 1). that prematurity was associated with lower weight and length. Preterm neonates showed significantly lower weight Preterm Infants Showed Marked Leukopenia (P < 0.001) and length (P = 0.044) than full-term neonates We compared the percentages of different immune subsets (Table 1), and weight and length values were directly cor- between the groups and observed that preterm infants had a related with GA (P < 0.001). Arterial pH values were higher higher percentage of total lymphocytes than full-term neo- in preterm infants (Table 1), although values were higher nates. We found that there were no significant differences in than 7.15 (which has been defined as the cutoff for acidosis the percentage of monocytes. In addition, the percentage of Table 1. Clinical data and percentages of immune cells in cord blood samples from preterm and full-term infants n Preterm n Term P value Infant characteristics Wk 117 33 (31–35) 94 39.6 (38–40.9) 0.000 Weight (g) 110 2,050 (1,539–2,540) 91 3,300 (3,070–3,570) 0.000 Length (cm) 16 47.7 (44.2–49) 19 49.5 (48–51) 0.044 Arterial pH 107 7.34 (7.29–7.38) 81 7.28 (7.22–7.33) 0.000 Maternal age 108 31 (26.3–35) 85 31 (28–35) NS % Total lymphocytes 21 45.93 (36.3–59.4) 17 31.09 (26.96–35.3) 0.000 % CD4+ Ta 103 47.8 (42.4–54.5) 83 44.38 (38.01–51.1) 0.011 % CD8+ Ta 103 17.96 (14.5–22.2) 83 16.15 (13.56–19.6) 0.048 % NK cellsa 105 7.09 (3.8–11.8) 84 10.62 (4.98–18.4) 0.004 % B cellsa 103 15.84 (11.9–20.8) 83 17.91 (14.1–23.07) 0.029 % T cells CD127+a 29 90.9 (89.8–92.2) 18 92.3 (90.9–93) 0.029 % Monocytesb 23 9.73 (7.2–11.1) 18 8.69 (7.48–10.11) NS % Basophilsb 23 1.14 (0.89–1.44) 18 0.84 (0.61–1) NS % Granulocytesb 23 40.03 (26.1–51.5) 18 56.49 (53.03–59.9) 0.000 % Neutrophilsc 23 84.12 (73.3–87.2) 18 89.42 (84.2–92.85) 0.002 % Eosinophilsc 23 9.66 (5.19–13.53) 18 4.04 (2.85–6.67) 0.020 % Immature Grns.c 23 8.15 (3.72–9.75) 18 6.06 (3.22–8.48) NS % CD4+ T celld % Naive 80 92.3 (71.4–95.6) 77 90.08 (70.3–95.9) NS % Memory 78 2.77 (1.6–4.6) 77 3.03 (1.8–4.79) NS % Activated 15 0.99 (0.7–2.4) 16 1.48 (0.98–1.92) NS % Effector 80 0.10 (0.03–0.2) 77 0.05 (0.02–0.17) NS % RTEs 23 51.7 (46.5–60.6) 17 64.79 (49.11–69.7) NS % Tregs 29 8.97 (7.25–10.07) 19 6.91 (6.12–7.91) 0.001 % CD4+CD127+ 29 89.2 (88–90.7) 18 90.9 (89.9–92.1) 0.013 % CD8+ T cellsd % Naive 78 88.5 (81.4–93) 77 89.43 (85.61–93.2) NS % Memory 78 1.85 (0.35–4.68) 77 2.32 (0.63–4.2) NS % Activated 15 0.31 (0.23–0.39) 16 0.26 (0.21–0.38) NS % Effector 78 1.06 (0.29–3.12) 77 0.89 (0.24–2.77) NS % RTEs 23 77.06 (70.8–84.8) 17 80.31 (76.01–84.2) NS Values are given as median (25th–75th percentiles). P value ≥ 0.05 by two-sided test was considered nonsignificant. Grns., granulocytes; NK, natural killer; NS, nonsignificant; RTEs, recent thymic emigrants; Tregs, regulatory T cells. aPercentages of cells in the total lymphocyte population. bPercentages of cells in the total of live cells. cPercentages of cells in the total granulocyte population. dPercentages of subpopulations in the CD4+ or CD8+ T cells. Copyright © 2012 International Pediatric Research Foundation, Inc. Volume 71 | Number 5 | May 2012 Pediatric RESEARCH 591 Articles Correa-Rocha et al. total granulocytes was lower, probably due to the significantly more premature the infant, the lower the lymphocyte values.
Load more

Recommended publications
  • Agammaglobulinemia Hypogammaglobulinemia Hereditary Disease Immunoglobulins
    Pediat. Res. 2: 72-84 (1968) Agammaglobulinemia hypogammaglobulinemia hereditary disease immunoglobulins Hereditary Alterations in the Immune Response: Coexistence of 'Agammaglobulinemia', Acquired Hypogammaglobulinemia and Selective Immunoglobulin Deficiency in a Sibship REBECCA H. BUCKLEY[75] and J. B. SIDBURY, Jr. Departments of Pediatrics, Microbiology and Immunology, Division of Immunology, Duke University School of Medicine, Durham, North Carolina, USA Extract A longitudinal immunologic study was conducted in a family in which an entire sibship of three males was unduly susceptible to infection. The oldest boy's history of repeated severe infections be- ginning in infancy and his marked deficiencies of all three major immunoglobulins were compatible with a clinical diagnosis of congenital 'agammaglobulinemia' (table I, fig. 1). Recurrent severe in- fections in the second boy did not begin until late childhood, and his serum abnormality involved deficiencies of only two of the major immunoglobulin fractions, IgG and IgM (table I, fig. 1). This phenotype of selective immunoglobulin deficiency is previously unreported. Serum concentrations of the three immunoglobulins in the youngest boy (who also had a late onset of repeated infection) were normal or elevated when he was first studied, but a marked decline in levels of each of these fractions was observed over a four-year period (table I, fig. 1). We could find no previous reports describing apparent congenital and acquired immunologic deficiencies in a sibship. Repeated infections and demonstrated specific immunologic unresponsiveness preceded gross ab- normalities in the total and fractional gamma globulin levels in both of the younger boys (tables II-IV). When the total immunoglobulin level in the second boy was 735 mg/100 ml, he failed to respond with a normal rise in titer after immunization with 'A' and 'B' blood group substances, diphtheria, tetanus, or Types I and II poliovaccines.
    [Show full text]
  • Ataxia Telangiectasia: a Diagnostic Challenge. Case Report
    case reports 2020; 6(2) https://doi.org/10.15446/cr.v6n2.83219 ATAXIA TELANGIECTASIA: A DIAGNOSTIC CHALLENGE. CASE REPORT Keywords: Ataxia Telangiectasia; Neurodegenerative Diseases; Cerebellar Ataxia; Spinocerebellar Degenerations; Telangiectasia. Palabras clave: Ataxia telangiectasia; Enfermedades neurodegenerativas; Ataxia cerebelosa; Degeneraciones espinocerebelosa; Telangiectasia. Natalia Martínez-Córdoba Universidad Militar Nueva Granada - Faculty of Medicine - Pediatric Neurology Research Group - Bogotá D.C. - Colombia. Hospital Militar Central - Pediatric Neurology Service - Bogotá D.C. - Colombia. Eugenia Espinosa-García Universidad Militar Nueva Granada - Faculty of Medicine - Pediatric Neurology Research Group - Bogotá D.C. - Colombia. Hospital Militar Central - Pediatric Neurology Service - Bogotá D.C. - Colombia. Universidad del Rosario - Medical School - Bogotá D.C. - Colombia. Corresponding author Natalia Martínez-Córdoba. Faculty of Medicine, Universidad Militar Nueva Granada. Bogotá D.C. Colombia. Email: [email protected]. Received: 28/10/2019 Accepted: 08/01/2020 case reports Vol. 6 No. 2: 109-17 110 RESUMEN ABSTRACT Introducción. La ataxia-telangiectasia (AT) es Introduction: Ataxia-telangiectasia (AT) is a un síndrome neurodegenerativo con baja inciden- neurodegenerative syndrome with low incidence cia y prevalencia mundial que es causado por una and prevalence worldwide, which is caused by a mutación del gen ATM, es de herencia autosó- mutation of the ATM gene. It is an autosomal re- mica recesiva y se asocia a mecanismos defec- cessive disorder that is associated with defective tuosos en la regeneración y reparación del ADN. cell regeneration and DNA repair mechanisms. It Este síndrome se caracteriza por la presencia de is characterized by progressive cerebellar atax- ataxia cerebelosa progresiva, movimientos ocula- ia, abnormal eye movements, oculocutaneous res anormales, telangiectasias oculocutáneas e telangiectasias and immunodeficiency.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Neonatal Leukopenia and Thrombocytopenia
    Neonatal Leukopenia and Thrombocytopenia Vandy Black, M.D., M.Sc., FAAP March 3, 2016 April 14, 2011 Objecves • Summarize the differenHal diagnosis of leukopenia and/or thrombocytopenia in a neonate • Describe the iniHal steps in the evaluaon of a neonate with leukopenia and/or thrombocytopenia • Review treatment opHons for leukopenia and/ or thrombocytopenia in the NICU Clinical Case 1 • One day old male infant admiUed to the NICU for hypoglycemia and a sepsis rule out • Born at 38 weeks EGA by SVD • Birth weight 4 lbs 13 oz • Exam shows a small cephalohematoma; no dysmorphic features • PLT count 42K with an otherwise normal CBC Definions • Normal WBC count 9-30K at birth – Mean 18K • What is the ANC and ALC – <1000/mm3 is abnormal – 6-8% of infants in the NICU • Normal platelet count: 150-450,000/mm3 – Not age dependent – 22-35% of infants in the NICU have plts<150K Neutropenia Absolute neutrophil count <1500/mm3 Category ANC* InfecHon risk • Mild 1000-1500 None • Moderate 500-1000 Minimal • Severe <500 Moderate to Severe (Highest if <200) • Recurrent bacterial or fungal infecHons are the hallmark of symptomac neutropenia! • *ANC = WBC X % (PMNs + Bands) / 100 DefiniHon of Neutropenia Black and Maheshwari, Neoreviews 2009 How to Approach Cytopenias • Normal vs. abnormal (consider severity) • Malignant vs. non-malignant • Congenital vs. acquired • Is the paent symptomac • Transient, recurrent, cyclic, or persistent How to Approach Cytopenias • Adequate vs. decreased marrow reserve • Decreased producHon vs. increased destrucHon/sequestraon Decreased neutrophil/platelet producon • Primary – Malignancy/leukemia/marrow infiltraon – AplasHc anemia – Genec disorders • Secondary – InfecHous – Drug-induced – NutriHonal • B12, folate, copper Increased destrucHon/sequestraon • Immune-mediated • Drug-induced • Consumpon à Hypersplenism vs.
    [Show full text]
  • On Lupus, Vitamin D and Leukopenia
    r e v b r a s r e u m a t o l . 2 0 1 6;5 6(3):206–211 REVISTA BRASILEIRA DE REUMATOLOGIA w ww.reumatologia.com.br Original article On lupus, vitamin D and leukopenia ∗ Juliana A. Simioni, Flavia Heimovski, Thelma L. Skare Rheumatology Unit, Hospital Universitário Evangélico de Curitiba, Curitiba, PR, Brazil a r t i c l e i n f o a b s t r a c t Article history: Background: Immune regulation is among the noncalcemic effects of vitamin D. So, this Received 7 October 2014 vitamin may play a role in autoimmune diseases such as systemic lupus erythematosus Accepted 24 June 2015 (SLE). Available online 4 September 2015 Objectives: To study the prevalence of vitamin D deficiency in SLE and its association with clinical, serological and treatment profile as well as with disease activity. Keywords: Methods: Serum OH vitamin D3 levels were measured in 153 SLE patients and 85 controls. Data on clinical, serological and treatment profile of lupus patients were obtained through Systemic lupus erythematosus Vitamin D chart review. Blood cell count and SLEDAI (SLE disease activity index) were measured simul- Leukopenia taneously with vitamin D determination. Granulocytopenia Results: SLE patients have lower levels of vitamin D than controls (p = 0.03). In univariate analysis serum vitamin D was associated with leukopenia (p = 0.02), use of cyclophos- phamide (p = 0.007) and methotrexate (p = 0.03). A negative correlation was verified with prednisone dose (p = 0.003). No association was found with disease activity measured by SLEDAI (p = 0.88).
    [Show full text]
  • Interactions of the Classical and Alternate Complement Pathway with Endotoxin Lipopolysaccharide EFFECT on PLATELETS and BLOOD COAGULATION
    Interactions of the Classical and Alternate Complement Pathway with Endotoxin Lipopolysaccharide EFFECT ON PLATELETS AND BLOOD COAGULATION Michael A. Kane, … , Joseph E. May, Michael M. Frank J Clin Invest. 1973;52(2):370-376. https://doi.org/10.1172/JCI107193. Research Article The contributions of the classical and alternate pathways of complement activation to the biological effects of endotoxin have been examined in the guinea pig, with particular reference to thrombocytopenia, leukopenia, and the development of the hypercoagulable state. Injection of endotoxin into normal guinea pigs led to a 95% fall in the level of circulating platelets within 15 min as well as a fall in circulating granulocytes. C4-deficient guinea pigs, known to have a complete block in the activity of the classical complement pathway, but with the alternate pathway intact, sustained no fall in platelets. The development of granulocytopenia proceeded normally. Endotoxin did activate the alternate complement pathway in C4D guinea pigs, as evidenced by the fall in C3-9 titers. With restoration of serum C4 levels, endotoxin- induced thrombocytopenia was observed in C4D animals. Thus, function of the classical complement pathway was an absolute requirement for the development of thrombocytopenia. Experiments performed in cobra venom factor (CVF)- treated normal guinea pigs, with normal levels of C1, C4, and C2, but with less than 1% of serum C3-9 demonstrated the importance of the late components in the development of thrombocytopenia but not leukopenia. C4-deficient guinea pigs had normal clotting times demonstrating that C4 was not required for normal clotting. In addition, development of the hypercoagulable state, evidenced by a marked shortening of the clotting […] Find the latest version: https://jci.me/107193/pdf Interactions of the Classical and Alternate Complement Pathway with Endotoxin Lipopolysaccharide EFFECT ON PLATELETS AND BLOOD COAGULATION MICHAEL A.
    [Show full text]
  • Blood and Immunity
    Chapter Ten BLOOD AND IMMUNITY Chapter Contents 10 Pretest Clinical Aspects of Immunity Blood Chapter Review Immunity Case Studies Word Parts Pertaining to Blood and Immunity Crossword Puzzle Clinical Aspects of Blood Objectives After study of this chapter you should be able to: 1. Describe the composition of the blood plasma. 7. Identify and use roots pertaining to blood 2. Describe and give the functions of the three types of chemistry. blood cells. 8. List and describe the major disorders of the blood. 3. Label pictures of the blood cells. 9. List and describe the major disorders of the 4. Explain the basis of blood types. immune system. 5. Define immunity and list the possible sources of 10. Describe the major tests used to study blood. immunity. 11. Interpret abbreviations used in blood studies. 6. Identify and use roots and suffixes pertaining to the 12. Analyse several case studies involving the blood. blood and immunity. Pretest 1. The scientific name for red blood cells 5. Substances produced by immune cells that is . counteract microorganisms and other foreign 2. The scientific name for white blood cells materials are called . is . 6. A deficiency of hemoglobin results in the disorder 3. Platelets, or thrombocytes, are involved in called . 7. A neoplasm involving overgrowth of white blood 4. The white blood cells active in adaptive immunity cells is called . are the . 225 226 ♦ PART THREE / Body Systems Other 1% Proteins 8% Plasma 55% Water 91% Whole blood Leukocytes and platelets Formed 0.9% elements 45% Erythrocytes 10 99.1% Figure 10-1 Composition of whole blood.
    [Show full text]
  • Immunodeficiency Disorders Ivan K
    Immunodeficiency Disorders Ivan K. Chinn, MD,*† Jordan S. Orange, MD, PhD‡x *Department of Pediatrics, Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX †Center for Human Immunobiology, Texas Children’s Hospital, Houston, TX ‡Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY xNew York Presbyterian Morgan Stanley Children’s Hospital, New York, NY Education Gaps Immunodeficiencies are no longer considered rare conditions. Although susceptibility to infections has become well-recognized as a sign of most primary immunodeficiencies, some children will present with noninfectious manifestations that remain underappreciated and warrant evaluation by an immunologic specialist. Providers must also consider common secondary causes of immunodeficiency in children. Objectives After completing this article, readers should be able to: 1. Recognize infectious signs and symptoms of primary immunodeficiency that warrant screening and referral to a specialist. 2. Understand noninfectious signs and symptoms that should raise concern for primary immunodeficiency. 3. Determine appropriate testing for patients for whom immunodeficiency is suspected. AUTHOR DISCLOSURE Dr Chinn has disclosed that he is the recipient of a 4. Discuss the management of patients with primary immunodeficiency. Translational Research Program grant from the Jeffrey Modell Foundation. Dr Orange has 5. Appreciate secondary causes of immunodeficiency. disclosed that he is a consultant on the topic of therapeutic immunoglobulin for Shire, CSL Behring, and Grifols and that he serves on the scientific advisory board for ADMA Biologics. This commentary does contain a discussion of INTRODUCTION an unapproved/investigative use of a commercial product/device. Immunodeficiency disorders represent defects in the immune system that result in weakened or dysregulated immune defense.
    [Show full text]
  • Hyperimmunoglobulin E Syndrome: Genetics, Immunopathogenesis, Clinical Findings, And
    Hyperimmunoglobulin E syndrome: Genetics, immunopathogenesis, clinical findings, and TICLE R treatment modalities A Hassan Hashemi1,2, Masoumeh Mohebbi1,2, Shiva Mehravaran1,3, Mehdi Mazloumi2, Hamidreza Jahanbani-Ardakani4,5, Seyed-Hossein Abtahi4,5,6 1Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, 2Department of Ophthalmology, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, 4Isfahan Eye Research Center, Feiz Eye Hospital, Isfahan University of Medical Sciences, Isfahan, 5Isfahan Medical Students Research Center (IMSRC), Isfahan University of Medical Sciences, Isfahan, 6Department of Ophthalmology, Feiz Eye Hospital, 3 EVIEW Isfahan University of Medical Sciences, Isfahan, Iran, Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California, USA R The hyperimmunoglobulin E syndromes (HIESs) are very rare immunodeficiency syndromes with multisystem involvement, including immune system, skeleton, connective tissue, and dentition. HIES are characterized by the classic triad of high serum levels of immunoglobulin E (IgE), recurrent staphylococcal cold skin abscess, and recurrent pneumonia with pneumatocele formation. Most cases of HIES are sporadic although can be inherited as autosomal dominant and autosomal recessive traits. A fundamental immunologic defect in HIES is not clearly elucidated but abnormal neutrophil chemotaxis due to decreased production or secretion of interferon γ has main role in the immunopathogenesis of syndrome, also distorted Th1/Th2 cytokine profile toward a Th2 bias contributes to the impaired cellular immunity and a specific pattern of infection susceptibility as well as atopic‑allergic constitution of syndrome. The ophthalmic manifestations of this disorder include conjunctivitis, keratitis, spontaneous corneal perforation, recurrent giant chalazia, extensive xanthelasma, tumors of the eyelid, strabismus, and bilateral keratoconus.
    [Show full text]
  • Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs
    Specific Drugs Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs Chief Editors: Ana Dioun Broyles, MD, Aleena Banerji, MD, and Mariana Castells, MD, PhD Ana Dioun Broyles, MDa, Aleena Banerji, MDb, Sara Barmettler, MDc, Catherine M. Biggs, MDd, Kimberly Blumenthal, MDe, Patrick J. Brennan, MD, PhDf, Rebecca G. Breslow, MDg, Knut Brockow, MDh, Kathleen M. Buchheit, MDi, Katherine N. Cahill, MDj, Josefina Cernadas, MD, iPhDk, Anca Mirela Chiriac, MDl, Elena Crestani, MD, MSm, Pascal Demoly, MD, PhDn, Pascale Dewachter, MD, PhDo, Meredith Dilley, MDp, Jocelyn R. Farmer, MD, PhDq, Dinah Foer, MDr, Ari J. Fried, MDs, Sarah L. Garon, MDt, Matthew P. Giannetti, MDu, David L. Hepner, MD, MPHv, David I. Hong, MDw, Joyce T. Hsu, MDx, Parul H. Kothari, MDy, Timothy Kyin, MDz, Timothy Lax, MDaa, Min Jung Lee, MDbb, Kathleen Lee-Sarwar, MD, MScc, Anne Liu, MDdd, Stephanie Logsdon, MDee, Margee Louisias, MD, MPHff, Andrew MacGinnitie, MD, PhDgg, Michelle Maciag, MDhh, Samantha Minnicozzi, MDii, Allison E. Norton, MDjj, Iris M. Otani, MDkk, Miguel Park, MDll, Sarita Patil, MDmm, Elizabeth J. Phillips, MDnn, Matthieu Picard, MDoo, Craig D. Platt, MD, PhDpp, Rima Rachid, MDqq, Tito Rodriguez, MDrr, Antonino Romano, MDss, Cosby A. Stone, Jr., MD, MPHtt, Maria Jose Torres, MD, PhDuu, Miriam Verdú,MDvv, Alberta L. Wang, MDww, Paige Wickner, MDxx, Anna R. Wolfson, MDyy, Johnson T. Wong, MDzz, Christina Yee, MD, PhDaaa, Joseph Zhou, MD, PhDbbb, and Mariana Castells, MD, PhDccc Boston, Mass; Vancouver and Montreal,
    [Show full text]
  • Immunology of the Acquired Immunodeficiency Syndrome
    Henry Ford Hospital Medical Journal Volume 32 Number 2 Article 6 6-1984 Immunology of the Acquired Immunodeficiency Syndrome Patrick W. McLaughlin Carl B. Lauter Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation McLaughlin, Patrick W. and Lauter, Carl B. (1984) "Immunology of the Acquired Immunodeficiency Syndrome," Henry Ford Hospital Medical Journal : Vol. 32 : No. 2 , 107-115. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol32/iss2/6 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. Henry Ford Hospital Med J Vol. 32, No. 2, 1984 Immunology of the Acquired Immunodeficiency Syndrome Patrick W. McLaughlin, MD* and Carl B. Lauter, MD** The Acquired Immunodeficiency Syndrome (AIDS) first known to cause immunodeficiency. Simian AIDS, an recognized in 1981, has been extensively studied, and animal model of virus-induced immunodeficiency, is the most recent studies have demonstrated that its also discussed. Recommendations are made regarding defects extend well beyond the apparent deficient the interpretation and limitations of immune testing in cell-mediated immunity to include humoral immunity, AIDS, includinga discussion of how apparently healthy autoimmunity, and abnormal immunoregulation. The homosexuals and groups at risk develop an immu­ recent discovery ofa retrovirus, HTLV III, as a possible nologic profile which mimics that of patients with AIDS. etiologic agent is discussed in relation to other viruses J\r\ce late 1981, an unexpected outbreak of oppor­ The immune system has "surveillance" functions to tunistic infections and unusual neoplasms has been protect humans (and other vertebrates) from infections noted, described, and studied (1-4).
    [Show full text]
  • Chronic Lymphocytic Leukemia Early Detection, Diagnosis, and Staging Detection and Diagnosis
    cancer.org | 1.800.227.2345 Chronic Lymphocytic Leukemia Early Detection, Diagnosis, and Staging Detection and Diagnosis Finding cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can be noticed, but that's not always the case. ● Can Chronic Lymphocytic Leukemia Be Found Early? ● Signs and Symptoms of Chronic Lymphocytic Leukemia ● How Is Chronic Lymphocytic Leukemia Diagnosed? Stages and Outlook (Prognosis) After a cancer diagnosis, staging provides important information about the extent of cancer in the body and anticipated response to treatment. ● How Is Chronic Lymphocytic Leukemia Staged? Questions to Ask About CLL Here are some questions you can ask your cancer care team to help you better understand your CLL diagnosis and treatment options. ● Questions to Ask About Chronic Lymphocytic Leukemia 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Can Chronic Lymphocytic Leukemia Be Found Early? For certain cancers, the American Cancer Society recommends screening tests1 in people without any symptoms, because they are easier to treat if found early. But for chronic lymphocytic leukemia (CLL) , no screening tests are routinely recommended at this time. Many times, CLL is found when routine blood tests are done for other reasons. For instance, a person's white blood cell count may be very high, even though he or she doesn't have any symptoms. If you notice any symptoms that could be caused by CLL, report them to your doctor right away so the cause can be found and treated, if needed. Hyperlinks 1. www.cancer.org/healthy/find-cancer-early/cancer-screening-guidelines/american- cancer-society-guidelines-for-the-early-detection-of-cancer.html Last Revised: May 10, 2018 Signs and Symptoms of Chronic Lymphocytic Leukemia Many people with chronic lymphocytic leukemia (CLL) do not have any symptoms when it is diagnosed.
    [Show full text]